LNTH Q4 2025

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Earnings

Lantheus delivered a strong fourth quarter beat to close out fiscal 2025, with adjusted diluted EPS of $1.67 topping the $1.17 consensus estimate by 42.92% and revenue of $406.79 million running 10.83% ahead of the $367.03 million Wall Street expecte… Read more Lantheus delivered a strong fourth quarter beat to close out fiscal 2025, with adjusted diluted EPS of $1.67 topping the $1.17 consensus estimate by 42.92% and revenue of $406.79 million running 10.83% ahead of the $367.03 million Wall Street expected, even as top-line growth of 4.0% year-over-year reflected a portfolio in transition. The headline numbers were lifted by the addition of Neuraceq, which contributed $31.00 million following Lantheus's acquisition of Life Molecular Imaging, and a 203.3% surge in strategic partnerships revenue, which more than offset a 9.7% decline in flagship PYLARIFY to $240.20 million. GAAP net income swung to $54.09 million from a loss of $11.79 million a year ago, largely due to the absence of a prior-year unrealized loss on equity securities. The recent FDA approval of PYLARIFY TruVu, a new formulation designed to expand production capacity and access, is seen as a catalyst for re-acceleration in the second half of 2026, though Lantheus's full-year guidance of $1.40 billion to $1.45 billion in revenue and adjusted EPS of $5.00 to $5.25 signals continued near-term pressure as the company reshapes its radiopharmaceutical portfolio.